Anti-APOBEC3G (full length) polyclonal antibody

Antibody Isotype

IgG

Species Reactivity

Human

Immunogen

Full length protein corresponding to Human APOBEC3G aa 1-384. (AAH24268.1)Sequence: MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLD AKIFRGQVYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKC TRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMK IMNYDEFQHCWSKFVYSQ

Conjugate

Application Notes

WB: 1 μg/ml.

Alternative Names

APOBEC3G; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G; DNA dC->dU-editing enzyme APOBEC-3G; bK150C2.7; CEM15; dJ494G10.1; FLJ12740; MDS019; DNA dC-> dU-editing enzyme APOBEC-3G; APOBEC-related protein 9; dU editing enzyme; phorboli

Entrez Gene ID

UniProt ID

Antigen Description

DNA deaminase (cytidine deaminase) that mediates a form of innate resistance to retroviral infections (at least to HIV-1 infection) by triggering G-to-A hypermutation in the newly synthesized viral DNA. The replacements C-to-U in the minus strand DNA of HIV-1 during reverse transcription, leads to G-to-A transitions in the plus strand. The inhibition of viral replication is either due to the degradation of the minus strand before its integration or to the lethality of the hypermutations. Modification of both DNA strands is not excluded. This antiviral activity is neutralized by the virion infectivity factor (VIF), that prevents the incorporation of APOBEC3G into progeny HIV-1 virions by both inhibiting its translation and/or by inducing its ubiquitination and subsequent degradation by the 26S proteasome. APOBEC3G binds a variety of RNAs, but does not display detectable APOB, NF1 and NAT1 mRNA editing.

Pathway

APOBEC3G mediated resistance to HIV-1 infection; Disease; HIV Infection; Host Interactions of HIV factors; Vif-mediated degradation of APOBEC3G;